Paul Calabresi Career Development Award for Clinical Oncology (K12 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

The purpose of the Paul Calabresi Career Development Award for Clinical Oncology (PCACO) is to increase the number of clinician-scientists (M.D.s, D.O.s, Pharm.D.s, nurses with Ph.D.s, or equivalent) trained in clinical and translational cancer research, and to promote their career development as cancer researchers.

This Funding Opportunity Announcement (FOA) allows appointment of Scholars proposing to serve as the lead investigator of an independent clinical trial; or proposing a separate ancillary clinical trial to an existing trial; or proposing to gain research experience in a clinical trial led by another investigator, as part of their research and career development.

Application Due Date(s):  June 18, 2019; June 17, 2020; June 17, 2021

PAR-19-242 Expiration/Closing Date: June 18, 2021

Agency Website

Eligibility Requirements

The sponsoring institution must assure support for the proposed program. Appropriate institutional commitment to the program includes the provision of adequate staff, facilities, and educational resources that can contribute to the planned program.

The applicant institution must have a strong and high-quality research program in the area(s) proposed under this FOA and must have the requisite faculty and facilities on site to conduct the proposed institutional program. It is anticipated that the proposed program will complement other ongoing career development programs occurring at the applicant institution and that a substantial number of program faculty will have active research projects in which participating Scholars may gain relevant experiences consistent with their research interests and goals.

The PD/PI should be an established investigator in the scientific area in which the application is targeted and capable of providing both administrative and scientific leadership to the development and implementation of the proposed program. The PD/PI will be responsible for the selection and appointment of Scholars to the approved career development program and for the overall direction, management, administration, and evaluation of the program. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required. The PD/PI has responsibility for the day-to-day administration of the program and is responsible for appointing members of the Advisory Committee (when applicable), using their recommendations to determine the appropriate allotment of funds. The PD/PI will be expected to monitor and assess the program and submit all documents and reports as required.

The PD(s)/PI(s) must hold ongoing R01 and/or R01-like cancer-focused grant support. For the NCI K12, R01 or R01-like awards are defined as grants or contracts of at least 3 years in duration and $150,000 per year in direct costs, including those supporting clinical trials.

      Amount Description

      Direct costs are limited to $50,000 in the initial year of new (Type 1) programs and may be used for curriculum planning and development, advertising and recruiting of the first class of Scholars. K12 scholars will begin work in the second year of the grant, where costs are limited to $750,000 in direct costs annually. For renewal (Type 2) applications, the program may request up to $750,000 in direct costs annually in each of the 5 years.

      Funds may be used only for those expenses that are directly related to and necessary for the career development of K12 Scholars, and must be expended in conformance with OMB Cost Principles and the NIH Grants Policy Statement.

      The award budget includes salary support for the PD(s)/PI(s) and Scholars, research and development support and administrative support costs.

      The project award duration for this funding opportunity may not exceed 5 years.   

      Funding Type

      Award
      Grant

      Eligibility

      Faculty

      Category

      Curriculum Development
      Medical
      Medical - Clinical Science
      Medical - Translational

      External Deadline

      June 18, 2019